Skip to main content
GoodMoatv1.1
Sign in
AEON logo

AEON

CompareEarnings: May 31, 2026

AEON Biopharma Inc - Class A

Exchange: NYSE MKTSector: HealthcareIndustry: Biotechnology

Priveterra Acquisition Corp - Class A

Did you know?

Price sits at 49% of its 52-week range.

Current Price

$0.89

-9.16%
Profile
Valuation (TTM)
Market Cap$10.52M
P/E-0.27
EV—
P/B—
Shares Out11.84M
P/Sales—
Revenue$0.00
EV/EBITDA—

AEON Biopharma Inc - Class A (AEON) Financial Statements

AEON Financial Data

EBITDA$-39.14M
Revenue (TTM)$0.00
Gross Profit (TTM)$0.00
Gross Margin—
Operating Margin—
ROE—
ROA-705.43%
Debt/Equity—
Current Ratio0.49
FCF$-17.31M
FCF Yield-164.53%
Piotroski F-Score—
Rev/Share (TTM)—
50-Day MA$1.10
200-Day MA$0.93
Shares Outstanding0.01B

AEON Computed Insights

FCF$-17.31M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%

Income Statement

Balance Sheet

Cash Flow Statement

AEON Financial Statements & Data

AEON Biopharma Inc - Class A (AEON) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of AEON Biopharma Inc - Class A's financial performance and position as a Healthcare company.

Trailing twelve-month (TTM) revenue is $0.00. Gross profit (TTM) is $0.00. EBITDA is $-39.14M. Earnings per share (EPS) is $-3.95. The P/E ratio is -0.27. Market capitalization is $10.52M.

Free cash flow (FCF) is $-17.31M. Weighted average cost of capital (WACC) is 10.00%.

Historical revenue data covers 6 years from FY20 to FY25. Net income history spans 6 years. Free cash flow and capital expenditure data spans 6 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.

Use AEON Biopharma Inc - Class A's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.